Filter by tags: Clinical trial Clear all tag filters
6 news articles found
Medical isotopes are radioactive substances used in various diagnostic and therapeutic procedures to treat various types of cancers and other conditions. They are essential for modern medicine, allowing physicians to visualise and target specific organs, tissues and cells in a patient’s body.
Over more than a decade, personalised medicine using nuclear techniques has been gaining pace, allowing doctors to tailor therapies and treatments to the specific needs and physiology of a patient, and to avoid harm to healthy organs or tissues.
According to Sven Van den Berghe, chief executive of Belgium-based isotope producer PanTera, one technique that has seen significant advances is known as theranostics – the term used to describe the combination of using one radioactive drug to diagnose and a second to deliver therapy to treat the main tumour and any metastatic tumours.
- Source: Nucnet
- Date: Friday, 14 April 2023
- Original article: nucnet.org/news/sector-aims-to-tackle-isotope-supply-problems-as-excitement-grows-over-targeted-therapies-4-4-2023
There are important lessons to be learned from the approaches that led to the rapid deployment of vaccines in the fight against the COVID-19 pandemic, James Naismith, professor of structural biology at the University of Oxford and director of the Rosalind Franklin Institute, told World Nuclear Association's Thinking Outside the Dome - Strategic eForum on Nuclear Innovation. The following is the text of his speech.
- Source: World Nuclear News
- Date: Friday, 25 June 2021
- Original article: world-nuclear-news.org/Articles/SPEECH-Learning-lessons-from-vaccine-development
Isotop JSC (part of Rusatom Healthcare, Rosatom’s radiation technologies integrator) on 9 June signed a five-year contract with Brazil’s Nuclear and Energy Research Institute (IPEN, part of the National Nuclear Energy Commission, CNEN) to supply medical isotopes lutetium-177 and actinium-225.
- Source: NEI Magazine
- Date: Friday, 11 June 2021
- Original article: neimagazine.com/news/newsrosatom-to-supply-brazil-with-key-medical-isotopes-8810883
Rusatom Healthcare, part of state nuclear corporation Rosatom, will build Russia’s first radiopharmaceutical plant to meet global GMP good manufacturing practice standards. The new production facility will be in Obninsk at the site of LYa Karpov Scientific Research Institute of Physics & Chemistry (NIFKhl) and will produce drugs for targeted cancer therapy. The design of pharmaceutical production will be carried out by the Central Design and Technological Institute. Pre-design work is planned to be completed this year, for commissioning in 2024 production in early 2025.
- Source: NEI Magazine
- Date: Friday, 07 August 2020
- Original article: neimagazine.com/news/newsrussia-to-open-radiopharmaceutical-plant-in-obninsk-8064702
The Australian Nuclear Science and Technology Organisation (Ansto) said a new radioactive variation of the element scandium, scandium-47, had been produced in the OPAL reactor.
- Source: NEI Magazine
- Date: Tuesday, 24 March 2020
- Original article: neimagazine.com/news/newsansto-develops-produces-scandium-47-for-the-first-time-7833921
A new radioactive version of the element scandium has been produced in Australia's OPAL reactor for the first time. Scandium-47 has the potential for theranostic use, that is, both as a therapeutic drug and a diagnostic agent, and has similar properties to lutetium-177, which is already being used in clinical trials.
- Source: World Nuclear News
- Date: Friday, 20 March 2020
- Original article: world-nuclear-news.org/Articles/Australia-produces-first-batch-of-medical-isotope